Novel plasmalogen derivative KIT-13 restores neurological function in a mouse model of Rett syndrome by reducing neuroinflammation and restoring mitochondrial function
Neurodevelopmental disorders, including Rett Syndrome (RTT), have no functional cure and cause substantial levels of disability. Neuroinflammation is now strongly associated with both neurodevelopmental disorders and neurodegenerative diseases, providing a strong rationale for development of novel therapeutics targeting common neuroinflammatory mechanisms. RTT is caused by mutations in the methylated DNA binding factor MECP2. Mecp2-deficient (Mecp2-KO) mice, which have been extensively characterized as a mouse model of RTT, exhibit high levels of neuroinflammation, mitochondrial dysfunction, and severe neurological symptoms similar to RTT patients. KIT-13 is a novel plasmalogen derivative being developed for the treatment of neurodevelopmental disorders including RTT. This study evaluated KIT-13 in both cell-based and in vivo models for its potential to inhibit neuroinflammation and address underlying mitochondrial dysfunction, as well as effects on RTT-like neurological symptoms in the RTT mouse model. Oral administration of KIT-13 to Mecp2-KO mice significantly reduced neurological symptoms assessed by a composite score evaluating mobility, gait, hindlimb clasping, tremor, breathing, and general condition and improved the life span of the RTT model mice. In addition, KIT-13 suppressed mitochondrial DNA leakage associated with Mecp2 deficiency, and significantly suppressed neuroinflammation as measured by microglial cell morphology. These results suggest that KIT-13 may be a promising therapeutic agent for RTT and other neuroinflammation-related diseases.